May 18, 2016
The whistleblower who in April lost a $219 million suit against Abbott Laboratories over allegedly improperly marketed bile duct stents won't get a new trial, a Texas federal judge ruled on Wednesday, finding that nothing in the proceeding led to an unfair trial.
May 06, 2016
The whistleblower who accused Abbott Laboratories of improperly marketing bile duct stents for off-label use asked a Texas federal judge Friday to grant a new trial after a jury in April cleared the medical device maker in a False Claims Act suit that sought $219 million in damages.
April 08, 2016
A jury verdict for Abbott Laboratories in a $200 million False Claims Act trial involving off-label marketing joins a string of recent defense wins in high-profile health fraud cases and suggests that the tide is turning after years of harsh financial penalties, attorneys say.
April 07, 2016
A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219 million in damages.
April 07, 2016
A former Abbott Laboratories sales-director-turned-whistleblower asked a Texas federal jury Thursday to find that the medical device manufacturer caused the submission of more than 35,000 false Medicare and Medicaid claims, costing the U.S. government more than $219 million.
April 01, 2016
A former Abbott Laboratories sales director fired back in Texas federal court Friday against the company's bid for a judge to shut down his False Claims Act suit, saying the jury heard enough evidence to hold Abbott responsible for $219 million in fraudulent Medicare claims.
March 25, 2016
A former Abbott Laboratories sales-director-turned-whistleblower told a Texas federal jury Friday he reported the company to federal investigators in an earnest belief it was best for the U.S. health care system, during a $219 million trial over allegedly false Medicare claims.
March 22, 2016
A former Abbott Laboratories sales director on Tuesday told a Texas federal jury the company charged Medicare $219 million for unauthorized uses of its stents, as a decade-old False Claims Act whistleblower case kicked off a three-week trial.
January 13, 2016
Abbott Laboratories asked a Texas federal judge Tuesday to rethink her decision forcing the company to face a whistleblower's False Claims Act lawsuit alleging it marketed stents for off-label uses, arguing that it need only show its marketing was "objectively reasonable" to evade the claims.
January 07, 2016
A Texas federal judge on Thursday denied bids by both Abbott Laboratories and a former employee who accuses the company of violating the False Claims Act by marketing stents for off-label uses to quickly end the suit, finding that too many questions about whether the devices qualified for Medicare billing remained.